feed,title,long_url,short_url
Benzinga,Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future,https://benzinga.com/analyst-ratings/analyst-color/23/05/32537616/blueprint-medicines-earns-higher-price-targets-post-fda-approval-analysts-optimisti,https://da.gd/xEES
